"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

Scott Whitaker sent a letter to HHS calling for staff cuts at the FDA to be reversed, arguing patient care and U.S.

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Agency chair Andrew Ferguson sent a memo to staff on Tuesday clarifying that Biden-era guidelines will remain in place — for ...

Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

The heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for ...

“We recognize that those with rare diseases often have complex needs that go unmet by traditional assistance,” said Green.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...